Treatments
RNA drug corrects calcium signaling in chimeric model of Timothy syndrome
The drug, tested in rats that have human neurons, could enter clinical testing as early as next year, researchers say.
RNA drug corrects calcium signaling in chimeric model of Timothy syndrome
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
A new look at walking in early childhood: Q&A with Rujuta Wilson
Quantifying toddlers’ gaits promises to improve autism diagnosis and intervention.
A new look at walking in early childhood: Q&A with Rujuta Wilson
Mutation in top autism-linked gene may alter eye reflex
The discovery could help clinicians diagnose children who carry mutations in the gene, called SCN2A, and gauge their responses to potential therapies.
Mutation in top autism-linked gene may alter eye reflex
New template streamlines sharing clinical trial results
This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.
New template streamlines sharing clinical trial results
Building bridges: Collaboration across the autism community
An autistic person and the mother of an autistic child explore partnership in the autism community.
Building bridges: Collaboration across the autism community
Journal club: Why do some children lose their autism diagnosis?
More than one-third of a cohort of autistic toddlers no longer meet criteria for the condition at school age, according to a new study, but the findings may not generalize because the cohort is predominantly white and affluent.
Journal club: Why do some children lose their autism diagnosis?
Uncertainty and excitement surround one company’s cell therapy for epilepsy
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
Uncertainty and excitement surround one company’s cell therapy for epilepsy
Brian Boyd, classroom-based interventions and the importance of representation
The leader of the Frank Porter Graham Child Development Institute talks about what drew him into the autism field, and his departure from — and return to — the University of North Carolina at Chapel Hill.
Brian Boyd, classroom-based interventions and the importance of representation
Looking at eye tracking’s potential for clinical trials
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
Looking at eye tracking’s potential for clinical trials
Explore more from The Transmitter
Crowdsourcing to curb aggression in autism: Q&A with Matthew Goodwin
To accelerate the development of real-time behavioral prediction technology, a research team is sharing data and seeking new collaborators.
Crowdsourcing to curb aggression in autism: Q&A with Matthew Goodwin
To accelerate the development of real-time behavioral prediction technology, a research team is sharing data and seeking new collaborators.
Brain connectivity and letting the data speak with Emily Finn
The Dartmouth College researcher talks about her quest to understand behavior and doing neuroscience “in the woods.”
Brain connectivity and letting the data speak with Emily Finn
The Dartmouth College researcher talks about her quest to understand behavior and doing neuroscience “in the woods.”
Carol Jennings, whose family’s genetics informed amyloid cascade hypothesis, dies at 70
Her advocacy work aided the discovery of a rare inherited form of early-onset Alzheimer’s disease and helped connect affected people with researchers.
Carol Jennings, whose family’s genetics informed amyloid cascade hypothesis, dies at 70
Her advocacy work aided the discovery of a rare inherited form of early-onset Alzheimer’s disease and helped connect affected people with researchers.